BioCentury
ARTICLE | Clinical News

Revlimid lenalidomide: Phase III started

May 5, 2014 7:00 AM UTC

Celgene disclosed in its 1Q14 earnings that it began the double-blind, international Phase III AUGMENT (NHL-007) trial to compare 20 mg oral Revlimid once daily for the first 3 weeks of a 4-week cycle for up to 12 cycles plus IV Rituxan rituximab vs. placebo plus Rituxan in about 350 patients with follicular lymphoma or marginal zone lymphoma. Celgene markets Revlimid in nearly 70 countries, including the U.S. and EU countries, in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM) in patients who have received >=1 prior therapy. The drug is also approved in the U.S. and EU to treat patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) with a 5q chromosomal deletion and in the U.S. for relapsed or refractory mantle cell lymphoma (MCL). ...